There has been little change in global TB incidence in the 21 century. Although case notification has increased, millions of people with TB each year remain unreached. Recently there has been increased recognition that many people with undiagnosed, potentially infectious TB do not experience or report TB symptoms. Symptom-agnostic screening (e.g. by chest X-ray) can effectively identify such forms of TB. While this activity is increasing globally and is beneficial to individuals screened, current levels fall far short of what is needed to impact transmission and population-level prevalence. Significant scale-up of symptom-agnostic screening across communities is required to improve treatment coverage and interrupt transmission. While there are major political, financial and health system challenges to undertaking such scale-up this is not without precedent. In the mid 20 century, in many countries which now experience a low TB burden, population level chest X-ray screening was successfully undertaken and contributed to the decline in TB. In this article we explore the challenges and opportunities that face countries wanting to scale-up symptom-agnostic screening and reflect on important lessons from the past.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2025.107875DOI Listing

Publication Analysis

Top Keywords

symptom-agnostic screening
12
chest x-ray
8
scale-up symptom-agnostic
8
screening
5
scaling-up symptom-agnostic
4
symptom-agnostic community-wide
4
community-wide screening
4
screening global
4
global tuberculosis
4
tuberculosis elimination
4

Similar Publications

There has been little change in global TB incidence in the 21 century. Although case notification has increased, millions of people with TB each year remain unreached. Recently there has been increased recognition that many people with undiagnosed, potentially infectious TB do not experience or report TB symptoms.

View Article and Find Full Text PDF

Finding and treating both tuberculosis disease and latent infection during population-wide active case finding for tuberculosis elimination.

Front Med (Lausanne)

October 2023

WHO Collaborating Centre for Tuberculosis and the Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia.

In recognition of the high rates of undetected tuberculosis in the community, the World Health Organization (WHO) encourages targeted active case finding (ACF) among "high-risk" populations. While this strategy has led to increased case detection in these populations, the epidemic impact of these interventions has not been demonstrated. Historical data suggest that population-wide (untargeted) ACF can interrupt transmission in high-incidence settings, but implementation remains lacking, despite recent advances in screening tools.

View Article and Find Full Text PDF

Background: Amid all public health measures to contain COVID-19, the most challenging has been how to break the transmission chain. This has been even more challenging in low- and middle-income countries (LMICs). A public health emergency warrants a public health perspective, which comes down to prevention.

View Article and Find Full Text PDF

Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model.

Curr Neuropharmacol

February 2023

Sorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, Paris, France.

Article Synopsis
  • Comprehensive omics and functional enrichment research in oncology has led to the development of treatments based on molecular pathways, with the potential for use in other medical fields like psychiatry and neurology.
  • The review focuses on the β-site amyloid precursor protein cleaving enzyme (BACE) and its impact on neurological and psychiatric disorders, suggesting a shared genetic and biological basis among conditions like Alzheimer's and autism.
  • The authors argue for a shift from traditional symptom-focused models to biology-based strategies in clinical neurology and psychiatry, proposing that advanced techniques in systems biology could enhance therapeutic approaches.
View Article and Find Full Text PDF

Developing the ATX(N) classification for use across the Alzheimer disease continuum.

Nat Rev Neurol

September 2021

Neurology Business Group, Eisai Inc., Woodcliff Lake, NJ, USA.

Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional clinical symptom-based definition to a clinical-biological construct along a temporal continuum. The AT(N) system is a symptom-agnostic classification scheme that categorizes individuals using biomarkers that chart core AD pathophysiological features, namely the amyloid-β (Aβ) pathway (A), tau-mediated pathophysiology (T) and neurodegeneration (N). This biomarker matrix is now expanding towards an ATX(N) system, where X represents novel candidate biomarkers for additional pathophysiological mechanisms such as neuroimmune dysregulation, synaptic dysfunction and blood-brain barrier alterations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!